Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Medical Microbiology and Immunology
Published in: Medical Microbiology and Immunology 2/2008

01-06-2008 | Original Investigation

Evaluation of recombinant modified vaccinia Ankara virus-based rhesus cytomegalovirus vaccines in rhesus macaques

Authors: Yujuan Yue, Zhongde Wang, Kristina Abel, Jinliang Li, Lisa Strelow, Angelo Mandarino, Meghan K. Eberhardt, Kimberli A. Schmidt, Don J. Diamond, Peter A. Barry

Published in: Medical Microbiology and Immunology | Issue 2/2008

Login to get access

Abstract

A vaccine consisting of rhesus cytomegalovirus (RhCMV) pp65-2, gB and IE1 expressed via modified vaccinia Ankara (MVA) was evaluated in rhesus macaques with or without prior priming with expression plasmids for the same antigens. Following two MVA treatments, comparable levels of anti-gB, pp65-2 and neutralizing antibody responses, and pp65-2- and IE1-specific cellular immune responses were detected in both vaccinated groups. Similar reductions in plasma peak viral loads were observed in these groups compared to untreated controls. This study demonstrates the immunogenicity and protective efficacy of rMVA-based RhCMV subunit vaccines in a primate host and warrants further investigation to improve the efficacy of subunit vaccines against CMV.
Literature
1.
Adler SP, Plotkin SA, Gonczol E, Cadoz M, Meric C, Wang JB, Dellamonica P, Best AM, Zahradnik J, Pincus S, Berencsi K, Cox WI, Gyulai Z (1999) A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne). J Infect Dis 180:843–846CrossRefPubMed
2.
Baroncelli S, Barry PA, Capitanio JP, Lerche NW, Otsyula M, Mendoza SP (1997) Cytomegalovirus and simian immunodeficiency virus coinfection: longitudinal study of antibody responses and disease progression. JAIDS 15:5–15PubMed
3.
Barry PA, Chang WLW (2007) Primate betaherpesviruses. In: Arvin A, Campadielli G, Moore P, Mocarski E, Roizman B, Whitley R, Yamanishi K (eds) Human herpesviruses: biology, therapy and Immunoprophylaxis. Cambridge University Press, London
4.
Barry PA, Lockridge KM, Salamat S, Tinling SP, Yue Y, Zhou SS, Gospe SM Jr, Britt WJ, Tarantal AF (2006) Nonhuman primate models of intrauterine cytomegalovirus infection. ILAR J 47:49–64CrossRefPubMed
5.
Buxbaum S, Kraus FB, Hahn A, Beck O, Kabartas B, Doerr HW, Ludwig B (2006) Flow cytometric analysis of virus-specific T lymphocytes: practicability of detection of HCMV-specific T lymphocytes in whole blood in patients after stem cell transplantation. J Immunol Methods 311:164–173CrossRefPubMed
6.
Chang WL, Tarantal AF, Zhou SS, Borowsky AD, Barry PA (2002) A recombinant rhesus cytomegalovirus expressing enhanced green fluorescent protein retains the wild-type phenotype and pathogenicity in fetal macaques. J Virol 76:9493–9504CrossRefPubMedPubMedCentral
7.
Drexler I, Staib C, Sutter G (2004) Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential? Curr Opin Biotechnol 15:506–512CrossRefPubMedPubMedCentral
8.
Fowler KB, Stagno S, Pass RF (2003) Maternal immunity and prevention of congenital cytomegalovirus infection. JAMA 289:1008–1011CrossRefPubMed
9.
Fowler KB, Stagno S, Pass RF, Britt WJ, Boll TJ, Alford CA (1992) The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med 326:663–667CrossRefPubMed
10.
Gonczol E, Berensci K, Pincus S, Endresz V, Meric C, Paoletti E, Plotkin SA (1995) Preclinical evaluation of an ALVAC (canarypox)—human cytomegalovirus glycoprotein B vaccine candidate. Vaccine 13:1080–1085CrossRefPubMed
11.
12.
Huff JL, Eberle R, Capitanio J, Zhou SS, Barry PA (2003) Differential detection of B virus and rhesus cytomegalovirus in rhesus macaques. J Gen Virol 84:83–92CrossRefPubMed
13.
Loomis-Huff JE, Eberle R, Lockridge KM, Rhodes G, Barry PA (2001) Immunogenicity of a DNA vaccine against herpes B virus in mice and rhesus macaques. Vaccine 19:4865–4873CrossRefPubMed
14.
Nigro G, Adler SP, La Torre R, Best AM (2005) Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 353:1350–1362CrossRefPubMed
15.
Pass RF, Duliege AM, Boppana S, Sekulovich R, Percell S, Britt W, Burke RL (1999) A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. J Infect Dis 180:970–975CrossRefPubMed
16.
Robinson HL, Montefiori DC, Villinger F, Robinson JE, Sharma S, Wyatt LS, Earl PL, McClure HM, Moss B, Amara RR (2006) Studies on GM-CSF DNA as an adjuvant for neutralizing Ab elicited by a DNA/MVA immunodeficiency virus vaccine. Virology 352:285–294CrossRefPubMed
17.
Schleiss MR, Bourne N, Bernstein DI (2003) Preconception vaccination with a glycoprotein B (gB) DNA vaccine protects against cytomegalovirus (CMV) transmission in the guinea pig model of congenital CMV infection. J Infect Dis 188:1868–1874CrossRefPubMed
18.
Schleiss MR, Bourne N, Stroup G, Bravo FJ, Jensen NJ, Bernstein DI (2004) Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine. J Infect Dis 189:1374–1381CrossRefPubMed
19.
Stratton KR, Durch JS, Lawrence RS (2000) Vaccines for the 21st century: a tool for decisionmaking. National Academy Press, Washington, DC
20.
Wang Z, La Rosa C, Lacey SF, Maas R, Mekhoubad S, Britt WJ, Diamond DJ (2006) Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection. J Clin Virol 35:324–331CrossRefPubMed
21.
Wang Z, La Rosa C, Li Z, Ly H, Krishnan A, Martinez J, Britt WJ, Diamond DJ (2007) Vaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1. Vaccine 25:1132–1141CrossRefPubMed
22.
Wang Z, La Rosa C, Maas R, Ly H, Brewer J, Mekhoubad S, Daftarian P, Longmate J, Britt WJ, Diamond DJ (2004) Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus. J Virol 78:3965–3976CrossRefPubMedPubMedCentral
23.
Wyatt LS, Belyakov IM, Earl PL, Berzofsky JA, Moss B (2008) Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA. Virology (in press)
24.
Yeager AS, Grumet FC, Hafleigh EB, Arvin AM, Bradley JS, Prober CG (1981) Prevention of transfusion-acquired cytomegalovirus infections in newborn infants. J Pediatr 98:281–287CrossRefPubMed
25.
Yue Y, Kaur A, Eberhardt MK, Kassis N, Zhou SS, Tarantal AF, Barry PA (2007) Immunogenicity and protective efficacy of DNA vaccines expressing rhesus cytomegalovirus glycoprotein B, phosphoprotein 65-2, and viral interleukin-10 in rhesus macaques. J Virol 81:1095–1109CrossRefPubMed
26.
Yue Y, Kaur A, Zhou SS, Barry PA (2006) Characterization and immunological analysis of the rhesus cytomegalovirus homologue (Rh112) of the human cytomegalovirus UL83 lower matrix phosphoprotein (pp65). J Gen Virol 87:777–787CrossRefPubMed
27.
Yue Y, Zhou SS, Barry PA (2003) Antibody responses to rhesus cytomegalovirus glycoprotein B in naturally infected rhesus macaques. J Gen Virol 84:3371–3379CrossRefPubMed
28.
Zhong J, Khanna R (2007) Vaccine strategies against human cytomegalovirus infection. Expert Rev Anti Infect Ther 5:449–459CrossRefPubMed
Metadata
Title
Evaluation of recombinant modified vaccinia Ankara virus-based rhesus cytomegalovirus vaccines in rhesus macaques
Authors
Yujuan Yue
Zhongde Wang
Kristina Abel
Jinliang Li
Lisa Strelow
Angelo Mandarino
Meghan K. Eberhardt
Kimberli A. Schmidt
Don J. Diamond
Peter A. Barry
Publication date
01-06-2008
Publisher
Springer Berlin Heidelberg
Published in
Medical Microbiology and Immunology / Issue 2/2008
Print ISSN: 0300-8584
Electronic ISSN: 1432-1831
DOI
https://doi.org/10.1007/s00430-008-0074-5

Other articles of this Issue 2/2008

Medical Microbiology and Immunology 2/2008 Go to the issue

Review

MHC class I immune evasion in MCMV infection

Review

The functions of herpesvirus-encoded microRNAs

Review

Murine cytomegalovirus regulation of NKG2D ligands

Review

Phenotypes of major immediate-early gene mutants of mouse cytomegalovirus

Review

The history of cytomegalovirus and its diseases

Review

Correlation of dendritic cell maturation and the formation of aggregates of poly-ubiquitinated proteins in the cytosol
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits